Research map: The next generation of antibody–drug conjugates

Back to the article

Papers in this map

  1. Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors · Jonathan Strosberg · 2017 · 3312 citations · Cited by this paper
  2. Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial · 2026 · Related
  3. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer · Shanu Modi · 2022 · 2707 citations · Cited by this paper
  4. Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial · 2026 · Related
  5. Unlocking the potential of antibody–drug conjugates for cancer therapy · Joshua Z. Drago · 2021 · 1164 citations · Cited by this paper
  6. FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial · 2026 · Related
  7. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer · Thomas B. Powles · 2024 · 1079 citations · Cited by this paper
  8. Data rights are the missing pillar for modernizing consent in medicine · 2026 · Related
  9. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial · Funda Meric‐Bernstam · 2023 · 1061 citations · Cited by this paper
  10. Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection · 2026 · Related
  11. Antibody–drug conjugates come of age in oncology · Charles Dumontet · 2023 · 849 citations · Cited by this paper
  12. Multi-omics maps human–pig interactions in extracorporeal liver cross-circulation · 2026 · Related
  13. Next generation antibody drugs: pursuit of the 'high-hanging fruit' · Paul J. Carter · 2017 · 779 citations · Cited by this paper
  14. Oligonucleotide–siRNA conjugate for SOD1 amyotrophic lateral sclerosis: a phase 1 trial · 2026 · Related
  15. Bystander killing effect of DS ‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity · Yusuke Ogitani · 2016 · 752 citations · Cited by this paper
  16. The genetic architecture of fibromyalgia across 2.5 million individuals · 2026 · Related
  17. Cleavable linkers in antibody–drug conjugates · Jonathan D. Bargh · 2019 · 662 citations · Cited by this paper
  18. Individualized antisense oligonucleotides for SCN2A-related developmental epileptic encephalopathy · 2026 · Related
  19. Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing · Hans K. Erickson · 2006 · 585 citations · Cited by this paper
  20. Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study · 2026 · Related
  21. Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity · Gene M. Dubowchik · 2002 · 567 citations · Cited by this paper
  22. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index · Robert P. Lyon · 2015 · 559 citations · Cited by this paper
  23. Site-selective modification strategies in antibody–drug conjugates · Stephen J. Walsh · 2020 · 463 citations · Cited by this paper
  24. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial · Fernanda Mosele · 2023 · 394 citations · Cited by this paper
  25. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial · Fabrice André · 2023 · 374 citations · Cited by this paper
  26. Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition · Junko Murai · 2014 · 293 citations · Cited by this paper
  27. A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model · Tomomi Nakayama Iwata · 2018 · 290 citations · Cited by this paper
  28. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer · James T. T. Coates · 2021 · 243 citations · Cited by this paper
  29. Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice · Yasuaki Anami · 2018 · 236 citations · Cited by this paper
  30. The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development · Raffaele Colombo · 2024 · 229 citations · Cited by this paper
  31. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial · Nadia Harbeck · 2024 · 218 citations · Cited by this paper
  32. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity · Shelley E. Ackerman · 2020 · 213 citations · Cited by this paper
  33. The therapeutic window of antibody drug conjugates: A dogma in need of revision · Raffaele Colombo · 2022 · 196 citations · Cited by this paper
  34. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity · Nina E. Weisser · 2023 · 184 citations · Cited by this paper
  35. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression · Aditya Bardia · 2024 · 179 citations · Cited by this paper
  36. ENHANZE ® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20 · Kenneth W. Locke · 2019 · 177 citations · Cited by this paper
  37. Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs · Julian Andreev · 2017 · 171 citations · Cited by this paper
  38. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody–Drug Conjugates · Niña G. Caculitan · 2017 · 168 citations · Cited by this paper
  39. Bispecific antibody drug conjugates: Making 1+1>2 · Yilin Gu · 2024 · 154 citations · Cited by this paper

Source: OpenAlex (CC0)